In investing and trading, understanding where expectations stand for a company or equity is half the battle. In the case of large, profitable listed companies, that’s often earnings expectations: a beat is only a beat because it topped market expectations. In the case of bio/pharma stocks, we make the same evaluations for binary events, like mid-stage study results.
Let’s look at two prescient situations that may present compelling opportunities in the coming days. 
Already a Premium user? Sign In
